Ascorbic acid is under clinical development by Renovion and currently in Phase I for Chronic Bronchitis. According to GlobalData, Phase I drugs for Chronic Bronchitis have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ascorbic acid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ascorbic acid overview
Ascorbic acid is under development for the treatment of lung dysfunction in lung transplant patients, patients with tracheostomy, chronic bronchitis and non-CF bronchiectasis, bronchiolitis obliterans syndrome (BOS) progression in participants with a bilateral lung transplant. It is administered through inhalational route. The drug candidate is developed as a nebulized therapy.
It was under development for primary ciliary dyskinesia (PCD), tracheostomy, cystic fibrosis, alpha-1 anti-trypsin deficiency (A1AD), chronic obstructive pulmonary disease (COPD).
Renovion overview
Renovion is a clinical stage pharmaceutical company that develops treatment for respiratory diseases. The company offers ARINA-1, a therapy that addresses deficiencies in the innate immune system. It provides a nebulized therapy to improve mucus clearance and pulmonary function and treat inflammatory lung and orphan pulmonary diseases, such as non-CF bronchiectasis to delay progression of deadly conditions. The company’s products are used to treat cystic fibrosis and lung transplantation. Renovion is headquartered in Chapel Hill, North Carolina, the US.
For a complete picture of Ascorbic acid’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
